Overview of attention for article published in Catheterization and Cardiovascular Interventions (Formerly Catheterization and Cardiovascular Diagnosis), November 2017
There are sparse clinical data on the procedural trends, outcomes and readmission rates following FDA approval and expansion of Transcatheter mitral valve repair/MitraClip(®) . Whether a complex new technology can be disseminated safely and quickly is controversial.
The study cohort was derived from the National Readmission Data (NRD) 2013-14. MitraClip(®) was identified using appropriate International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes. The primary outcome was a composite of in-hospital mortality + procedural complications. Secondary outcome included 30-day readmissions. Hierarchical two level logistic models were used to evaluate study outcomes.
Our analysis included 2003 MitraClip(®) procedures. Overall in-hospital mortality was 3.9%. As expected, there was a significant increase in procedural volume post-FDA approval. Importantly, a corresponding downward trend in mortality and procedural complications was observed. Significant predictors of in-hospital mortality and procedural complications included the use of vasopressors (P <0.001) and hemodynamic support (P < 0.001). Higher hospital volume (≥10 MitraClips/year) was associated with lower in-hospital mortality and complications (P = 0.02). There were 304 (15.1%) 30-day readmissions, with heart failure being the most common cause of readmission. Elective procedures had lower in-hospital mortality (P < 0.001) and lower readmission rates (P = 0.011) compared with nonelective procedures.
A significant increase in MitraClip(®) procedural volumes occurred post-FDA approval. Overall morbidity and mortality were low and trended downwards. Hospital procedure volume ≥10 cases were associated with lower mortality and overall complication rates. These data suggest a successful roll out of a very complex novel structural heart procedure.
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 December 2017.
All research outputs
#28,747,015
of 34,517,649 outputs
Outputs from Catheterization and Cardiovascular Interventions (Formerly Catheterization and Cardiovascular Diagnosis)
#4,227
of 4,761 outputs
Outputs of similar age
#393,165
of 492,621 outputs
Outputs of similar age from Catheterization and Cardiovascular Interventions (Formerly Catheterization and Cardiovascular Diagnosis)
#57
of 64 outputs
Altmetric has tracked 34,517,649 research outputs across all sources so far. This one is in the 9th percentile – i.e., 9% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,761 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one is in the 6th percentile – i.e., 6% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 492,621 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 64 others from the same source and published within six weeks on either side of this one. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.
